Show simple item record

Antibodies To Both Ro52 And Ro60 Define A Subset Of Sjogren'S Most Suitable For Clinical Trials Of Agents Targeting Lymphoproliferations

dc.contributor.authorArmagan, Berkan
dc.contributor.authorRobinson, Susan
dc.contributor.authorBazoberry, Adriana
dc.contributor.authorGrader-Beck, Thomas
dc.contributor.authorBaer, Alan
dc.date.accessioned2021-06-03T05:20:05Z
dc.date.available2021-06-03T05:20:05Z
dc.date.issued2019
dc.identifier.issn0003-4967
dc.identifier.urihttp://dx.doi.org/10.1136/annrheumdis-2019-eular.3387
dc.identifier.urihttp://hdl.handle.net/11655/23981
dc.language.isoen
dc.relation.isversionof10.1136/annrheumdis-2019-eular.3387
dc.rightsAttribution 4.0 United States
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleAntibodies To Both Ro52 And Ro60 Define A Subset Of Sjogren'S Most Suitable For Clinical Trials Of Agents Targeting Lymphoproliferations
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalAnnals Of The Rheumatic Diseases
dc.contributor.departmentİç Hastalıkları
dc.identifier.volume78
dc.identifier.issue2
dc.description.indexWoS


Files in this item

Name:
94.pdf
Size:
582.1Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 United States
Except where otherwise noted, this item's license is described as Attribution 4.0 United States